Skip to main content
. 2022 Apr 4;28(5):1014–1021. doi: 10.1038/s41591-022-01755-w

Fig. 2. Mean change from baseline (CFB) to month 12 in BCVA comparing treated and untreated eyes.

Fig. 2

Treated and untreated eye groups are shown for the pooled dose groups (n = 11) (a); the low-dose (160-µg/80-µg) group (n = 6) (b); and the mid-dose (320-µg/160-µg) group (n = 5) (c). Bars show s.e.m.; data are summarized in Supplementary Table 1. +Visual acuity changes associated with cataract events occurrence: eight patients developed cataracts in the treated eye (3/6 in the 160-µg/80-µg dose group and 5/5 in the 320-µg/160-µg dose group), and six cataracts required lens replacement. These patients regained their pre-cataract visual acuity after surgery. BL, baseline; M, month.